down arrow

Waters Corp.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9418481035
USD
396.37
-1.25 (-0.31%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

386.09397.62

52 Week

275.05423.56
Valuation
Technical
Day's Volume

CASH

626.54 k

Shareholding (Mar 2025)

FII

38.99%

Held by 374 FIIs

DII

21.38%

Held by 48 DIIs

Promoter

0.14%

How big is Waters Corp.?

22-Jun-2025

As of Jun 18, Waters Corp. has a market capitalization of $54.72 billion, with net sales of $2.98 billion and a net profit of $657 million over the latest four quarters.

Market Cap: As of Jun 18, Waters Corp. has a market capitalization of 54,718.27 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Waters Corp. reported net sales of 2,983.25 million and a net profit of 657.02 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,828.51 million and total assets of 4,553.80 million.

Read More

What does Waters Corp. do?

22-Jun-2025

Waters Corporation is a large-cap manufacturer of analytical instruments primarily for the Pharmaceuticals & Biotechnology industry, with quarterly net sales of $662 million and a net profit of $121 million as of March 2025. Key metrics include a P/E ratio of 85.00 and a return on equity of 33.82%.

Overview:<BR>Waters Corporation is an analytical instrument manufacturer operating in the Pharmaceuticals & Biotechnology industry, with a market capitalization in the large-cap bracket.<BR><BR>Financial Snapshot:<BR>- Net Sales: 662 Million (Quarterly Results - Mar 2025)<BR>- Net Profit: 121 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 54,718.27 Million (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 85.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.56<BR>- Return on Equity: 33.82%<BR>- Price to Book: 27.88<BR><BR>Contact Details:<BR>- Address: 34 MAPLE ST, MILFORD MA: 01757-3604<BR>- Tel: ['1 508 4782000', '1 508 4823448']<BR>- Fax: 1 508 8721990<BR>- Website: https://www.waters.com/nextgen/us/en.html

Read More

Who are in the management team of Waters Corp.?

22-Jun-2025

As of March 2022, the management team of Waters Corp. includes Chairman Christopher O'Connell, CEO Dr. Udit Batra, and several independent directors: Thomas Salice, Linda Baddour, Michael Berendt, Edward Conard, and Gary Hendrickson. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Waters Corp. includes the following individuals:<BR><BR>- Mr. Christopher O'Connell, Chairman of the Board<BR>- Dr. Udit Batra, President, Chief Executive Officer, and Director<BR>- Mr. Thomas Salice, Lead Independent Director<BR>- Ms. Linda Baddour, Independent Director<BR>- Dr. Michael Berendt, Independent Director<BR>- Mr. Edward Conard, Independent Director<BR>- Mr. Gary Hendrickson, Independent Director<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Waters Corp. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Waters Corp. is in a mildly bearish trend, with daily moving averages and KST indicating bearish signals, despite recent outperformance against the S&P 500 over the past week and month, while significantly underperforming year-to-date.

As of 3 October 2025, the technical trend for Waters Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the KST showing bearish signals on both weekly and monthly time frames. While the weekly MACD and Dow Theory suggest a mildly bullish outlook, the overall sentiment remains cautious due to the monthly indicators leaning bearish. <BR><BR>In terms of performance, Waters Corp. has outperformed the S&P 500 in the past week and month, but it has significantly underperformed over the year and since the beginning of the year, with returns of -7.06% and -11.69% compared to the S&P 500's 17.82% and 14.18%, respectively.

Read More

Is Waters Corp. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Waters Corp. is considered undervalued compared to its peers, with a high P/E ratio of 85 and an EV to EBITDA of 54.96, suggesting potential growth that may not be fully reflected in its price, despite its lower return of 19.67% over the past three years compared to the S&P 500's 81.19%.

As of 17 October 2025, the valuation grade for Waters Corp. has moved from expensive to attractive, indicating a shift in perception regarding its value. The company appears to be undervalued, particularly in comparison to its peers. Key valuation ratios include a P/E ratio of 85, an EV to EBITDA of 54.96, and a PEG ratio of 11.06, which suggest that despite its high valuations, there may be growth potential that is not fully reflected in the current price.<BR><BR>In the peer comparison, Waters Corp. has a P/E ratio significantly higher than ResMed, Inc. at 37.73 and Agilent Technologies, Inc. at 27.42, which are both in the same industry. Additionally, the EV to EBITDA ratio of 54.96 is higher than that of ResMed, which stands at 27.08, further emphasizing the relative valuation landscape. Over the past three years, Waters Corp. has returned 19.67%, while the S&P 500 has significantly outperformed with a return of 81.19%, highlighting a potential opportunity for investors as the stock may be undervalued relative to its growth prospects.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 47.77%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.17 times

 
3

Poor long term growth as Net Sales has grown by an annual rate of 5.98% and Operating profit at 4.74% over the last 5 years

4

With ROCE of 27.82%, it has a fair valuation with a 18.75 Enterprise value to Capital Employed

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 49,633 Million (Mid Cap)

stock-summary
P/E

85.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.52

stock-summary
Return on Equity

30.68%

stock-summary
Price to Book

22.98

Revenue and Profits:
Net Sales:
771 Million
(Quarterly Results - Jun 2025)
Net Profit:
147 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
32.26%
0%
32.26%
6 Months
12.24%
0%
12.24%
1 Year
1.28%
0%
1.28%
2 Years
37.25%
0%
37.25%
3 Years
14.11%
0%
14.11%
4 Years
19.62%
0%
19.62%
5 Years
66.72%
0%
66.72%

Waters Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Waters Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Waters Corp. has moved from expensive to attractive, indicating a shift in perception regarding its value. The company appears to be undervalued, particularly in comparison to its peers. Key valuation ratios include a P/E ratio of 85, an EV to EBITDA of 54.96, and a PEG ratio of 11.06, which suggest that despite its high valuations, there may be growth potential that is not fully reflected in the current price. In the peer comparison, Waters Corp. has a P/E ratio significantly higher than ResMed, Inc. at 37.73 and Agilent Technologies, Inc. at 27.42, which are both in the same industry. Additionally, the EV to EBITDA ratio of 54.96 is higher than that of ResMed, which stands at 27.08, further emphasizing the relative valuation landscape. Over the past three years, Waters Corp. has returned 19.67%, while the S&P 500 has significantly outperformed with a return ...

Read More
Waters Corp. Experiences Valuation Adjustment Amidst Competitive Pharmaceuticals Landscape

Waters Corp. Experiences Valuation Adjustment Amidst Competitive Pharmaceuticals Landscape

Waters Corp., a midcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, showcasing a P/E ratio of 85 and a price-to-book value of 28.71. The company reports strong performance metrics, including a ROCE of 27.82% and an ROE of 33.82%, amidst a competitive industry landscape.

Read More

Is Waters Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Waters Corp. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued based on its current metrics. Key ratios include a P/E ratio of 85, an EV to EBITDA of 54.96, and a PEG ratio of 11.06, which suggest that despite the attractive valuation grade, the company is still trading at a premium compared to its peers. In comparison to its peers, Waters Corp. has a P/E ratio significantly higher than ResMed, Inc. at 37.73 and Agilent Technologies, Inc. at 27.42, indicating that it may be overvalued relative to these companies. However, its EV to EBITDA ratio is better than Mettler-Toledo International, Inc., which stands at 47.45. Over the past year, Waters Corp. has underperformed against the S&P 500, with a return of -3.66% compared to the index's 14.08%, highlighting potential concerns re...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
5.98%
EBIT Growth (5y)
4.74%
EBIT to Interest (avg)
14.34
Debt to EBITDA (avg)
1.17
Net Debt to Equity (avg)
0.56
Sales to Capital Employed (avg)
0.91
Tax Ratio
16.08%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
47.77%
ROE (avg)
133.16%
Valuation key factors
Factor
Value
P/E Ratio
85
Industry P/E
Price to Book Value
28.71
EV to EBIT
67.39
EV to EBITDA
54.96
EV to Capital Employed
18.75
EV to Sales
19.25
PEG Ratio
11.06
Dividend Yield
NA
ROCE (Latest)
27.82%
ROE (Latest)
33.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 129 Schemes (39.48%)

Foreign Institutions

Held by 374 Foreign Institutions (38.99%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 8.86% vs -4.33% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 3.08% vs -5.25% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "771.30",
          "val2": "708.50",
          "chgp": "8.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "239.80",
          "val2": "238.40",
          "chgp": "0.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "14.40",
          "val2": "23.70",
          "chgp": "-39.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.60",
          "val2": "-2.90",
          "chgp": "224.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "147.10",
          "val2": "142.70",
          "chgp": "3.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "244.00%",
          "val2": "269.90%",
          "chgp": "-2.59%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.07% vs -0.52% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -0.69% vs -9.27% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,958.40",
          "val2": "2,956.40",
          "chgp": "0.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,043.70",
          "val2": "1,009.50",
          "chgp": "3.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "89.70",
          "val2": "98.90",
          "chgp": "-9.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-26.30",
          "val2": "-26.20",
          "chgp": "-0.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "637.80",
          "val2": "642.20",
          "chgp": "-0.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "287.90%",
          "val2": "285.30%",
          "chgp": "0.26%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
771.30
708.50
8.86%
Operating Profit (PBDIT) excl Other Income
239.80
238.40
0.59%
Interest
14.40
23.70
-39.24%
Exceptional Items
3.60
-2.90
224.14%
Consolidate Net Profit
147.10
142.70
3.08%
Operating Profit Margin (Excl OI)
244.00%
269.90%
-2.59%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 8.86% vs -4.33% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 3.08% vs -5.25% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,958.40
2,956.40
0.07%
Operating Profit (PBDIT) excl Other Income
1,043.70
1,009.50
3.39%
Interest
89.70
98.90
-9.30%
Exceptional Items
-26.30
-26.20
-0.38%
Consolidate Net Profit
637.80
642.20
-0.69%
Operating Profit Margin (Excl OI)
287.90%
285.30%
0.26%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.07% vs -0.52% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -0.69% vs -9.27% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Waters Corp. stock-summary
stock-summary
Waters Corp.
Pharmaceuticals & Biotechnology
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. It also designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA product line. It is also a developer and supplier of software-based products that interface with the Company's instruments, as well as other suppliers' instruments. Its LC and LC-MS instruments are utilized in a range of industries to detect, identify, monitor and measure the chemical, physical and biological composition of materials, and to purify a range of compounds.
Company Coordinates stock-summary
Company Details
34 MAPLE ST , MILFORD MA : 01757-3604
stock-summary
Tel: 1 508 47820001 508 4823448
stock-summary
https://www.waters.com/nextgen/us/en.html
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."